MSF Challenges Pfizer Bid For India Prevenar Patent
This article was originally published in PharmAsia News
Executive Summary
Médecins Sans Frontières has opposed an Indian patent application by Pfizer for its best-selling pneumococcal conjugate vaccine (PCV13), saying the product is not sufficiently novel. The move comes as the country faces strong US and EU pressure to ease its stiff patent law while at the same time needing to reduce its number of child deaths, the highest in the world.
You may also be interested in...
Share Fillip As Indian Pharma Crests US Regulatory Hump
For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.
Biocon, Quark Win Pioneering Indian Nod For RNAi Eye Therapy Trial
Asia’s biggest biotech company, India’s Biocon Ltd, has announced it will conduct what it says is the first-ever clinical trial of a siRNA therapy in India with US partner Quark, is aimed at tackling a rare eye condition.
India To Overhaul Old Drug Law To Cover Medical Advances
Prime Minister Narendra Modi’s government has decided to "comprehensively review" India's antiquated drug legislation to take into account the latest medical developments and improve safety, amid complaints about poor-quality manufacturing and products.